PeptiCov

PeptiCov is focused on discovering and developing an effective treatment for SARS-CoV-2. PeptiCov is a spin-off company of PeptiCom, a biotechnology company that uses artificial intelligence to streamline peptide drug discovery. PeptiCom's AI technology streamlines and significantly accelerates the ability to discover advanced peptide-based drug candidates by searching an enormous set of possible solutions, vastly reducing the risk of failure during development. It covers more possible molecular options, while simultaneously filtering out the most suitable candidates with properties such as solubility and permeability. This software analyzed several protein targets related to the coronavirus SARS-CoV-2 and designed a number of potential peptide drug candidates that were lab validated. PeptiCov is responsible for further development of these peptides and seeking partnerships with pharmaceutical companies.

PeptiCov was founded in 2021 by Immanuel Lerner (Co-founder & CEO), Anwar Rayan (Co-founder ).

PeptiCov operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Biologicals, Artificial Intelligence. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals.

PeptiCov is based in Professor Racah St, Jerusalem, Israel, Jerusalem District.